Logo image
IRO Home Research units Researcher Profiles
Sign in
Oral Iptacopan Monotherapy: A New Frontier for Paroxysmal Nocturnal Hemoglobinuria
Letter/Communication

Oral Iptacopan Monotherapy: A New Frontier for Paroxysmal Nocturnal Hemoglobinuria

Anjali Sharathkumar
NEJM journal watch. Oncology & hematology
03/25/2024

View Online

Abstract

Iptacopan, a first-in-class oral factor B inhibitor, could provide an additional therapeutic option for treatment of PNH.
Hemoglobin Standard of care

Details

Metrics

2 Record Views
Logo image